Because CDDO-Me and its related synthetic triterpenoids have entered clinical trials as promising preventive and therapeutic agents for cancer and chronic inflammatory diseases, development of novel USP7-selective compounds based on the CDDO-Me scaffold warrant further investigation. The gene discussed is USP7; the disease is cancer.